An open-label study was performed in 2016 in the UK to analyze the feasibility, safety and efficacy of psilocybin in managing patients with unipolar treatment-resistant depression with promising effects; although the research was small and included only twelve people, seven of These clients achieved formal standards for remission a person week subs